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INTRODUCTION
Heavy menstrual bleeding (HMB) is a 
common and debilitating problem that can 
significantly affect the lives of women. With an 
annual community incidence of 25% among 
women aged 18–54 years,1 1 million seek 
help for this problem each year in the UK,2 
mostly in general practice,3 and it accounts 
for 12% of all gynaecology referrals.4 Despite 
the many factors influencing decisions not 
to seek help,5 the cost of health care for 
HMB is substantial. In a recent national 
audit of care of HMB in England and Wales, 
almost one-third of women had received no 
previous medical treatment before referral 
to secondary care, with over 40% having 
surgical intervention in the year following 
first attendance at hospital.6
The National Institute for Health and 
Care Excellence (NICE) defines HMB as that 
which interferes with a women’s physical, 
emotional, social, and material quality of 
life, and which can occur alone or with other 
symptoms.2 This recognises that patient 
perceptions of HMB and what they find 
troublesome does not correlate well with 
a traditional biomedical focus on volume 
of blood loss.7 For clinical practice, HMB 
should be regarded as more subjectively 
defined by patients, focusing on perceived 
impact on their lives rather than menstrual 
blood loss in itself;2,8 in addition to physical 
and psychological health, this includes 
interference with social, working, and family 
life, or the practical burden of sanitary care.9
At the commencement of the current 
trial, guidelines for HMB recommended 
that initial management should usually 
be medical, using either oral tranexamic 
acid or mefenamic acid; or using the 
combined oral contraceptive (COC), or 
the levonorgestrel-releasing intrauterine 
system (LNG-IUS) for women requiring 
contraception, or for those not requiring 
contraception but prepared to accept 
hormonal treatments.10 In 2007, similar 
guidelines from NICE recommended this 
range of pharmaceutical treatments, and 
underlined the potential for more patients 
with HMB to be managed by their GPs, 
avoiding secondary care.2
Five trials in gynaecological settings 
(involving 44–165 women, and 3–12 months 
follow-up) have found LNG-IUS more 
beneficial in reducing menstrual blood loss 
than treatments such as mefenamic acid 
or COC.11 However, evidence on how helpful 
treatments are in improving patients’ quality 
of life, or their use in primary care, is 
lacking.11 Previous findings from the current 
trial found that both LNG-IUS and usual 
medical treatments significantly reduced 
the effect of HMB on patients’ quality of 
life in the first 2 years of treatment, but 
LNG-IUS was more effective.12 HMB may, 
however, be chronic and episodic over 
several years.13 A recent Cochrane Review 
recommended that trials of at least 5 years 
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Background
Heavy menstrual bleeding (HMB) is a common, 
chronic problem affecting women and health 
services. However, long-term evidence on 
treatment in primary care is lacking.
Aim
To assess the effectiveness of commencing the 
levonorgestrel-releasing intrauterine system 
(LNG-IUS) or usual medical treatments for 
women presenting with HMB in general practice.
Design and setting
A pragmatic, multicentre, parallel, open-label, 
long term, randomised controlled trial in 63 
primary care practices across the English 
Midlands.
Method
In total, 571 women aged 25–50 years, with 
HMB were randomised to LNG-IUS or usual 
medical treatment (tranexamic/mefenamic 
acid, combined oestrogen–progestogen, or 
progesterone alone). The primary outcome was 
the patient reported Menorrhagia Multi-Attribute 
Scale (MMAS, measuring effect of HMB on 
practical difficulties, social life, psychological and 
physical health, and work and family life; scores 
from 0 to 100). Secondary outcomes included 
surgical intervention (endometrial ablation/
hysterectomy), general quality of life, sexual 
activity, and safety.
Results
At 5 years post-randomisation, 424 (74%) 
women provided data. While the difference 
between LNG-IUS and usual treatment groups 
was not significant (3.9 points; 95% confidence 
interval  = –0.6 to 8.3; P = 0.09), MMAS scores 
improved significantly in both groups from 
baseline (mean increase, 44.9 and 43.4 points, 
respectively; P<0.001 for both comparisons). 
Rates of surgical intervention were low in both 
groups (surgery-free survival was 80% and 77%; 
hazard ratio 0.90; 95% CI = 0.62 to 1.31; P = 0.6). 
There was no difference in generic quality of life, 
sexual activity scores, or serious adverse events. 
Conclusion
Large improvements in symptom relief across 
both groups show treatment for HMB can be 
successfully initiated with long-term benefit and 
with only modest need for surgery.
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are needed, which should include a focus 
on patients’ quality of life.11
Decisions made by women and their 
GPs about medical treatments for HMB 
also include wider dynamic considerations 
such as attitudes to using oral treatment 
or having an intrauterine device, changing 
plans about wanting to conceive or need 
for contraception, or anticipating surgical 
intervention. Thus, long-term evidence is 
needed to help guide decision making in 
practice.
In this pragmatic randomised controlled 
trial, outcomes at 5 years of commencing 
LNG-IUS or usual medical treatments were 
assessed for women presenting with HMB 
in primary care.
METHOD
Population
Women aged 25–50 years with HMB involving 
at least three consecutive menstrual cycles 
and who presented to their GP were eligible 
to participate. Women were excluded if 
they intended to become pregnant over 
the next 5 years, were taking hormone-
replacement therapy or tamoxifen, had 
intermenstrual bleeding (between expected 
periods), postcoital bleeding, or findings 
suggestive of fibroids (abdominally-
palpable uterus equivalent in size to that at 
10–12 weeks’ gestation), or other disorders, 
or had contraindications to or a preference 
for either the levonorgestrel-IUS or usual 
medical treatments. Women with heavy, 
irregular bleeding were ineligible unless the 
results of endometrial biopsy were reported 
to be normal; no further investigations 
were mandated by the protocol. All patients 
provided written informed consent.
Randomisation
Patients were assigned to a study group 
by telephone or a web-based central 
randomisation service at the University 
of Birmingham Clinical Trials Unit. A 
computerised, minimised randomisation 
procedure was used to achieve balance 
between the groups with respect to age 
(<35 years or ≥35 years), body-mass 
index (BMI kg/m2; <25 or ≥25), duration of 
symptoms (<1 year or ≥1 year), need for 
contraception (yes or no), and HMB alone 
or HMB accompanied by menstrual pain. 
Study interventions and compliance
Eligible women who provided written 
informed consent were randomly 
assigned to either LNG-IUS or usual 
medical treatment. Usual treatment 
options included oral tranexamic acid, 
mefenamic acid, norethisterone, a 
combined oestrogen–progestogen or 
progesterone-only oral contraceptive pill 
(any formulation), or medroxyprogesterone 
acetate injection; and were chosen by the 
clinician and patient on the basis of any 
contraceptive needs or the desire to avoid 
hormonal treatment.2,14 The particular 
medical treatment to be used was specified 
before randomisation. Subsequently, and in 
line with real-life practice, treatments could 
be changed (from one medical treatment 
to another, from the LNG-IUS to a usual 
medical treatment, or from a usual medical 
treatment to the LNG-IUS), or could be 
discontinued because of a perceived lack of 
benefit, side effects, a change in the need 
for contraception, referral for endometrial 
ablation or hysterectomy, or any other 
reasons according to usual clinical 
practice.2,14 Treatment changes reported by 
patients were confirmed with their GP.
Outcome measures and follow-up
The primary outcome measure was the 
patient-reported, condition-specific 
Menorrhagia Multi-Attribute Scale (MMAS) 
at 5 years follow-up.15,16 The MMAS is 
designed to measure the effect of HMB on 
six domains of daily life. Possible responses 
are not affected/slightly affected/moderately 
affected/severely affected for each domain. 
The scores for each domain are weighted 
according to the perceived importance of 
that domain to women with this condition. 
In order of importance, from highest to 
lowest, the domains are: family life and 
relationships; physical health; work and daily 
routine; practical difficulties; psychological 
health; social life. Summary scores, 
which range from 0 (severely affected) 
to 100 (not affected), were assessed. The 
MMAS has a high degree of reliability and 
internal consistency,15 good content and 
construct validity,17,18 is responsive,19,20 and is 
acceptable to responders.15,16,19,20
How this fits in 
Heavy menstrual bleeding is a chronic 
debilitating problem, and a common cause 
of gynaecological referral and surgery. 
Evidence is lacking about the long-term 
effectiveness of treatment in primary 
care. This trial shows that initiation of 
either the usual medical treatments or 
the levonorgestrel-releasing intrauterine 
system in general practice can safely help. 
These treatments reduce the effects of 
heavy menstrual bleeding on patients’ 
lives over a 5-year time course with most 
women avoiding surgery. 
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Secondary outcome measures included 
general health-related quality of life and 
sexual activity. To assess generic quality 
of life, three instruments were used: the 
Medical Outcomes Study 36-Item Short-
Form Health Survey (SF-36), version 2 (with 
scores ranging from 0 [severely affected] 
to 100 [not affected]); the EuroQoL Group 
5-Dimension Self-Report Questionnaire 
(EQ-5D) descriptive system (with scores 
ranging from –0.59 [health state worse 
than death] to 100 [perfect health state]); 
and the EQ-5D visual-analogue scale (with 
scores ranging from 0 [worst health state 
imaginable] to 100 [most perfect health 
state imaginable]). The validated Sexual 
Activity Questionnaire measures pleasure 
(with scores ranging from 0 [lowest level] to 
18 [highest level]), discomfort (with scores 
ranging from 0 [greatest] to 6 [none]), and 
frequency (assessed relative to perceived 
usual activity as an ordinal response).21 
Responses for all outcomes were obtained 
before randomisation and by post at 5 years 
after randomisation. Data were collected 
from participating GPs regarding all 
serious adverse events, defined as adverse 
events that resulted in death, disability, or 
hospitalisation. Patients were also asked 
to report any hospitalisations and adverse 
events leading to discontinuation of the 
study treatments.
Study oversight
Study oversight was provided by an 
independent steering committee and an 
independent data and safety monitoring 
committee, whose three reviews of interim 
data provided no reason to modify the trial 
protocol on the basis of pragmatic stopping 
criteria.22 The study was conducted in 
accordance with the protocol, available at 
www.nets.nihr.ac.uk/projects/hta/020602. 
All medications and devices were prescribed 
by providers through the NHSconfid. The 
manufacturers of any therapeutic agents 
used in the study were not involved in any 
aspect of the trial. 
Statistical considerations
The study was designed to have 90% power 
(at P<0.05) to detect a small-to-moderate 
difference23 — 0.3 of a standard deviation 
(SD) — in the primary outcome. This required 
responses from 470 patients; the sample 
size was increased to 570 to allow for up to 
20% loss to follow-up. At 5 years follow-up 
424 responses were received; a post-hoc 
calculation suggested that this total would 
provide 87% power (P = 0.05) to detect the 
same size of difference. For progression 
to surgical intervention (hysterectomy or 
endometrial ablation), using an assumed 
rate of 35% in the standard arm (a figure 
that was set out in the protocol), 424 women 
would provide 80% power (P = 0.05) to 
detect an absolute reduction of 12%, that is 
35% down to 23%.
Analyses were performed according to 
the intention-to-treat principle. Differences 
between groups at 5 years were examined 
by analysis of covariance (adjusting for 
baseline score). Changes between baseline 
score within groups were examined using 
paired t-tests. The primary analysis was 
based on some patients declining to 
complete the MMAS, indicating on the form 
that they were no longer bleeding and the 
questions did not appear relevant to them. 
Thus, these patients were assigned the 
best possible score (100). This assumption 
was further tested through sensitivity 
analyses by making no assumption about 
those questionnaires that were returned 
blank, that is MMAS scores were assumed 
to be missing. Kaplan–Meier plots were 
constructed for a time to surgery and a 
time to treatment change analysis, with 
women censored at date to last follow-
up or, if appropriate, date to death, 
withdrawal or loss to follow-up. A Cox 
proportional hazards model was used to 
construct hazard ratios (HRs). Surgery-free 
analysis was then re-performed, excluding 
participants who crossed over from one 
treatment group to another. All the effect 
sizes are presented with 95% confidence 
intervals (CIs) and P-values. All tests and 
corresponding P-values were two-sided. 
Table 1. Characteristics of the patients
  Usual medical treatment, n (%) LNG-IUS, n (%)
N  286 285
Age, years ≥35a 255 (89) 257 (90)
 Mean (SD) 41.8 (5.5) 42.1 (5.0)
Body mass index, kg/m2 ≥25a 200 (70) 200 (70)
 Mean (SD) 29.3 (6.7) 29.1 (6.1)
Ethnic groupb White 246 (86) 225 (79)
 Asian 23 (8) 28 (10)
 Black 12 (4) 18 (6)
 Mixed 4 (1) 9 (3)
 Other 1 (<1) 4 (1)
Duration of heavy menstrual bleeding ≥1 yeara 229 (80) 231 (81)
Presence of menstrual paina  211 (74) 213 (75)
Contraceptive requirementa   55 (19) 55 (19)
Copper or non-hormonal coil in place 10 (3) 9 (3) 
LNG-IUS =  levonorgestrel-releasing intrauterine system. aThis characteristic was a minimisation variable and was 
assessed in the pre-defined subgroup analyses. bSelf-identified ethnic grouping; one ‘not given’ response in the LNG-
IUS group.
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The statistical package SAS (version 9.2) 
was used for all the statistical analysis. 
RESULTS
Patients and follow-up
Between February 2005 and July 2009, a total 
of 571 women with HMB from 63 primary 
care centres were randomly assigned to 
either the LNG-IUS (285 women) or usual 
medical treatment (286 women). Baseline 
characteristics were similar between the 
two treatment groups (Table 1). 
For 215 (75%) of the women assigned 
to usual medical treatment, the initial 
prescription was for mefenamic acid, 
tranexamic acid, or a combination of the two 
drugs; 55 (19%) of the women in the usual 
treatment group required contraception.
Study-questionnaire booklets were 
returned by 424 (74%) of participants at 
5 years (Figure 1). One-hundred and fifteen 
women (27%) indicated that they were 
no longer having periods and so did not 
complete the MMAS section. 
These women completed other sections 
of the questionnaire and still contributed to 
the analysis of MMAS responses.
The proportion of patients still taking 
their allocated treatment at 5 years was 
47% (95% CI = 40% to 52%) in the LNG-IUS 
group and 15% (95% CI = 11% to 20%) in the 
usual treatment group (Figure 2). 
Of the 228 recorded instances of 
treatment change in women allocated 
usual medical treatment, 97 (43%) were to 
LNG-IUS. In the LNG-IUS group, 57 out of 
148 (39%) treatment switches were to usual 
treatment. 
Reported reasons for discontinuation of 
treatment were varied, with lack of treatment 
efficacy most commonly cited (24% [36 out 
of 148] in the LNG-IUS group and 41% [94 
out of 228] in the usual treatment group). 
Further details are summarised in 
Appendices 1 and 2 (available from authors 
on request).
Figure 1. Enrolment, randomisation and follow-up for up to 5 years of the study patients. aSee Figure 2 for time to first treatment change survival estimates. bReasons 
reported for discontinuing treatment available from the authors on request.
1132 approached for consent after 
meeting eligibility criteria
571 females randomised
561 not randomised
- 190 had preference for usual medical treatment
- 130 had preference for LNG-IUS
- 86 declined to participate
- 25 wanted referral to secondary care
- 3 did not want any treatment
- 3 intended to become pregnant
- 124 no reason given
286 allocated to usual 
medical treatment
6 did not take treatment 
- 1 had LNG-IUS insertion
- 5 decided to take no treatment
285 allocated to LNG-IUS
24 did not have insertion
- 10 decided to have usual medical 
 treatment 
- 8 unsuccessful insertions, given 
 usual medical treatment
- 6 decided to take no treatment
69 exited trial
- 1 died
- 39 lost to follow-up
- 29 contacted and did not 
 wish to complete any
 more questionnaires
78 exited trial
- 37 lost to follow-up
- 41 contacted and did not 
 wish to complete any
 more questionnaires
208 returned 
questionnaire booklet at 5 years
222 recorded instances of 
discontinued treatmenta,b
- 96 had LNG-IUS insertion
- 126 decided to take no 
 treatment
216 returned questionnaire 
booklet at 5 years
124 recorded instances of 
discontinued treatmenta,b
- 39 changed to usual medical 
 treatment
- 85 decided to take no treatment
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Primary outcome: Menorrhagia Multi-
Attribute Scale (MMAS)
Women started out with average scores 
of approximately 40 points out of 100 
on the MMAS, indicating that they 
were substantially affected by HMB at 
presentation to their GP. 
At 5 years, these scores were significantly 
improved to >80 points out of 100 in both 
groups (Table 2). 
This improvement was higher on average 
among the women assigned to LNG-IUS 
but the difference was not statistically 
significant (3.9 points; 95% CI = –0.6 to 
8.3; P = 0.09). The same analysis without 
any assumption about MMAS scores, 
where the form was returned blank and 
the women indicated she was no longer 
bleeding, returned a similar result 
(5.2 points difference in favour of LNG-IUS; 
95% CI = –0.4 to 10.8; P = 0.07).
Surgical interventions 
Fifty-three events (endometrial ablation 
or hysterectomy) in the LNG-IUS group 
versus 56 in the usual treatment group 
were included in the surgery-free survival 
analysis (109 events in total). This difference 
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Figure 2. Time to first treatment change over 5 years 
follow-up.
Table 2. Menorrhagia Multi-Attribute Scale (MMAS) summary scores at baseline and 5 years follow-up
   Difference between   
	 Baseline score (SD, n)	 5 year score (SD, n)	 groups over 5 years	 Change within group (95% CI), P-value 
UMT	 LNG-IUS	 UMT	 LNG-IUS	 (95% CI)a, P-value	 UMT	 LNG-IUS
39.2 42.5 83.1 87.1 3.9 43.9 44.6 
(21.3, 269) (20.5, 280) (24.4, 208) (22.1, 216)  (–0.6 to 8.3), 0.09 (39.1 to 47.7), <0.0001 (41.0 to 48.8), <0.0001
Mean score (standard deviation, n) shown at each time-point. aPoint estimates (95% CI, P-values) shown for differences between groups and changes within group. Estimates 
>0 from differences between groups favour LNG-IUS. Results at each time-point adjusted for baseline score. Change within group compared to baseline. 0 = worst affected, 
100 = not affected. LNG-IUS =  levonorgestrel-releasing intrauterine system. UMT = usual medical treatment.
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Figure 3. Surgery-free (hysterectomy/endometrial 
ablation) survival analysis over 5 years of follow-up.
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was not statistically significant (HR 0.90; 
95% CI = 0.62 to 1.31; P = 0.6) (Figure  3). 
Analysis excluding participants who 
crossed over from one group to another 
returned a similar result (HR 0.96; 95% 
CI = 0.60 to 1.52; P = 0.9). Five-year surgery-
free survival rates were 80% (95% CI = 74% 
to 84%) in the LNG-IUS group versus 
77% (95% CI = 71% to 82%) in the usual 
treatment group. In total, there were 115 
surgical interventions: 24 ablations in the 
LNG-IUS group versus 31 in the usual 
treatment group and 30 hysterectomies in 
both groups (six more events than quoted 
above as six patients had both types of 
surgery).
Generic quality of life and sexual activity
Responses to the EuroQoL and SF-36 
instruments were generally significantly 
improved from baseline in both groups 
(Table 3); the only statistically significant 
difference between groups was seen in the 
general health perception domain of the 
SF-36 and favoured LNG-IUS (4.7 points, 
95% CI = 0.6 points to 8.8 points; P = 0.02). 
The treatment groups did not differ 
significantly with respect to any of the 
domains of the Sexual Activity Questionnaire.
Safety
There was no significant difference between 
the groups in the total number of serious 
Table 3. Scores on the quality-of-life and sexual activity questionnaires at baseline and 5 years follow-up
   Difference between    
 Baseline score (SD, n) 5 year score (SD, n) groups over 5 years Change within group (95 % CI), P-value
	 UMT	 LNG-IUS	 UMT	 LNG-IUS	 (95% CI)a, P-value	 UMT	 LNG-IUS
SF-36b
 Physical functioning 77.8 80.0 83.0 85.4 1.6 5.6 5.9 
 (24.7, 264) (20.4, 272) (26.3, 208) (23.5, 216) (–2.7 to 5.9), 0.5000 (1.8 to 9.5), 0.0040 (2.8 to 9.1), 0.0003
 Physical role 68.9 72.1 80.6 83.9 2.7  12.6 13.3 
 (26.2, 264) (24.7, 276) (27.2, 208) (25.5, 217) (–2.1 to 7.5), 0.3000 (7.9 to 17.2), <0.0001 (9.5 to 17.1) <0.0001
 Emotional role 69.8 71.9 83.3 81.4 –2.0  13.1 10.9 
 (26.8, 264) (25.1, 276) (25.3, 208) (26.9, 217) (–6.8 to 2.9), 0.4000 (8.7 to 17.6), <0.0001 (6.7 to 15.1), <0.0001
 Social functioning 62.4 64.3 76.9 79.5 2.2  14.0 15.6 
 (25.9, 268) (24.5, 277) (25.5, 207) (25.1, 214) (–2.5 to 6.9), 0.4000 (9.4 to 18.5), <0.0001 (11.6 to 19.6), <0.0001
 Mental health 59.0 60.3 72.6 71.4 –1.6  13.6 11.4 
 (19.8, 267) (19.3, 277) (19.4, 206) (20.5, 214) (–5.2 to 2.0), 0.4000 (10.5 to 16.7), <0.0001 (8.5 to 14.3), <0.0001
 Energy/vitality 40.8 40.7 56.6 59.2 2.8  15.7 18.6 
 (21.7, 268) (20.9, 277) (23.1, 206) (21.0, 213) (–1.2 to 6.9), 0.2000 (11.9 to 19.4), <0.0001 (15.2 to 22.0), <0.0001
 Pain 49.5 54.2 71.3 76.1 3.7 21.4 22.7 
 (24.9, 268) (24.9, 278) (28.6, 207) (24.8, 214) (–1.3 to 8.7), 0.1000 (16.9 to 25.8), <0.0001 (18.6 to 26.9), <0.0001
 General health perception 60.3 61.8 61.9 67.8 4.7 2.0  5.1 
 (21.9, 264) (21.4, 274) (23.8, 207) (22.1, 214) (0.6 to 8.8), 0.0200 (–1.5 to 5.6), 0.2600 (2.0 to 8.3), 0.0020
EuroQoL
 EQ-5D descriptive systemc 0.71 0.76 0.82 0.81 –0.02  0.10 0.06 
 (0.28, 269) (0.24, 277) (0.25, 207) (0.25, 214) (–0.06 to 0.02), 0.4000 (0.06 to 0.14), <0.0001 (0.02 to 0.09), 0.0030
 EQ-5D visual analogue scaled 69.7 70.3 76.1 77.3 0.6  6.3 6.5 
  (19.8, 246) (19.1, 250) (18.8, 198) (19.9, 207) (–3.2 to 4.5), 0.8000 (2.9 to 9.8), 0.0004 (3.0 to 9.9), 0.0003
Sexual	activity	questionnairee
 Pleasure 10.9 10.8 11.8 11.2 –0.4  0.6  0.1 
 (4.9, 199) (4.9, 210) (4.6, 100) (4.5, 111) (–1.7 to 0.9), 0.6000 (–0.6 to 1.7), 0.4000 (–1.0 to 1.2), 0.9000
 Discomfort 4.6 4.7 4.8 4.8 0.0  0.1  0.1  
 (1.7, 201) (1.5, 209) (1.6, 101) (1.6, 111) (–0.4 to 0.4), 0.9000 (–0.2 to 0.4), 0.7000 (–0.3 to 0.4), 0.7000
Mean score (standard deviation, n) shown at each time-point. Point estimates (95% CI, P-values) shown for differences between groups and changes within group. Estimates >0 
from differences between groups favour LNG-IUS. Results at each time-point adjusted for baseline score. Change within group compared with baseline. aEstimated values >0 
favour LNG-IUS. bThe Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) is a general health-related quality-of-life questionnaire. Scores in each of the eight 
domains range from 0 (severely affected) to 100 (not affected). cThe EuroQoL Group 5-Dimension Self-Report Questionnaire (EQ-5D) descriptive system is a general health-related 
quality-of-life questionnaire. Scores range from −0.59 (state of health worse than death) to 1.00 (perfect state of health). dScores on the EQ-5D visual-analogue scale range from 
0 (worst health state imaginable) to 100 (most perfect health state imaginable). eThe Sexual Activity Questionnaire is designed to assess the possible effect of treatment on sexual 
functioning. Scores for pleasure range from 0 (lowest level) to 18 (highest level), and scores for discomfort range from 0 (greatest) to 6 (none). LNG-IUS =  levonorgestrel-releasing 
intrauterine system. UMT = usual medical treatment.
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adverse events (P = 0.32). These are listed 
in Appendix 2 (available from authors on 
request).
DISCUSSION
Summary
This pragmatic trial shows that women 
affected by HMB can be effectively helped in 
primary care by initiating LNG-IUS or usual 
medical treatment, with long-term benefit, 
and only modest need for surgery. Women in 
either treatment group experienced similar 
and significant improvement in condition-
specific quality of life after 5 years. Women 
receiving usual medical treatment were no 
more likely to need surgical intervention 
than those treated with insertion of an 
LNG-IUS, with rates of surgical intervention 
(endometrial ablation or hysterectomy) 
remaining low in both groups (approximately 
20%). Generic quality of life scores were 
similarly improved in both groups and there 
was no difference in sexual activity scores or 
serious adverse events.
Strengths and limitations
This is the largest randomised trial 
available of medical treatments for HMB. 
Generalisability is strengthened by a 
pragmatic, multicentre design, mimicking 
treatment decisions in ‘real life’ primary 
care, involving a large sample ethnically 
representative of the UK population. 
Outcomes have been assessed in the longer 
term, appropriate to the chronic nature of 
HMB. This study used a validated patient-
centred primary outcome reflecting patients’ 
assessments of the impact of HMB on 
their quality of life, in line with guidance for 
assessing HMB,2 rather than a biomedical 
focus on menstrual blood loss itself. While 
use of indirect measures of menstrual 
blood loss were considered, pictorial blood 
assessment charts correlate poorly with 
blood loss and are not consistently accurate.8
Given 5 years since study entry, a relatively 
high follow-up has been sustained to include 
424 out of 571 (74%) women randomised. 
The range of drugs within the usual medical 
treatment group includes those used in 
routine practice, but it is acknowledged that 
this limits ability to compare any individually 
with the LNG-IUS. The intention-to-
treat analysis may be considered overly 
conservative by some; particularly given 
the long follow-up period but alternatives 
such as per protocol analyses are likely to 
exaggerate treatment effects as they restrict 
analyses to only those patients satisfied 
with treatment performance.24 While there 
was no statistically significant difference 
in primary outcome between the two 
groups, significant proportions of women 
reported that their periods had ceased, or 
had changed or ceased treatments, and 
this may have limited the ability to detect a 
difference. Such changes may be expected 
in real life over 5 years, however, and are 
consistent with experience from national 
audit of care for HMB.6
Comparison with existing literature
A 2015 Cochrane Review highlights the lack 
of research on the medical management of 
HMB in primary care, the need for evidence 
on HMB related quality of life outcomes, 
and for data from longer-term trials 
reporting beyond 2 years.11 The current 
trial contributes new evidence to these 
three gaps. The authors are not aware of 
similar long-term comparisons of medical 
treatments initiated in primary care. In 
secondary care, trials of similar length have 
compared LNG-IUS with hysterectomy25 
rather than other medical treatments, or 
endometrial resection to oral medication.26
The present results are encouraging in 
showing both HMB-specific and generic 
quality of life for women were significantly 
improved 5 years after commencing either 
usual medical treatment or LNG-IUS. 
The size of improvement — approximately 
equivalent to two SDs — is likely to be a very 
large effect.23 Women were considerably 
affected by HMB at presentation to their 
GP, and improvement in MMAS score 
from baseline (by 43.9 and 44.6 points for 
usual medical treatment or for LNG-IUS, 
respectively) reflects a clinical change 
of at least one category in all six MMAS 
domains (practical difficulties, social life, 
psychological health, physical health, 
work and daily routine, and family life and 
relationships) from being substantially to 
minimally affected by HMB; for example, 
from frequent to occasional disruptions of 
work and daily routine.
The greater clinical efficacy of LNG-IUS 
compared with usual medical treatments 
seen at 2 years in this trial12 has now 
diminished. At 5 years, only a borderline 
difference (P = 0.09) in favour of LNG-IUS 
has been observed. This was estimated to 
be 3.9 points on average, which is less than 
one-fifth of a SD and unlikely to be clinically 
meaningful. This may be unsurprising 
given the high proportions of women who, 
by 5 years after treatment allocation, had 
either changed to a treatment that worked 
for them, or had ceased bleeding either 
naturally or through surgical intervention. 
Retention rates at 5 years were 15% 
with usual medical treatment and 47% 
in the LNG-IUS group. This may reflect 
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greater impact on symptoms from using 
the LNG-IUS. Another factor may be that 
women could more easily choose to stop 
usual medical treatment when desired or 
according to their symptoms, without the 
need for consultation and removal of their 
intra-uterine device (IUD).
Natural cessation of bleeding or women 
stopping treatments may also explain the 
present data providing no evidence of any 
reduction in surgical interventions with LNG-
IUS compared with usual medical therapy, 
even when treatment cross-overs were 
discounted. At 2 years post-randomisation, 
surgical interventions were low at about 
10% in both medical treatment groups,12 
and this has approximately doubled to 20% 
in both groups at 5 years. This is still much 
lower than the 58% surgical intervention 
rate at 2 years identified in an earlier 
Cochrane Review of trials comparing oral 
medical therapy with surgical interventions 
for HMB, although these were in secondary 
care settings.27 The relatively low surgical 
intervention rates in the current trial may 
also possibly be explained by exclusion 
of women with enlarged uteri or known 
conditions such as fibroids that were 
deemed unsuitable for treatment in a 
community setting.
Implications for research and practice 
The present data have been obtained in 
the context of real-life clinical practice, for 
a chronic and episodic problem, where, 
as experienced in this trial, women 
may commonly discontinue or change 
treatments for their HMB.6 The inclusion 
criteria also underline that women who do 
not have a uterus palpable abdominally, 
or who have had normal investigation 
for irregular periods, can be successfully 
treated in primary care.
The results provide valuable practical 
information for women and GPs when 
weighing up choice of, and what to expect in 
the longer term from treatments for HMB. 
This needs to take account of individuals 
differing preferences for oral treatments or 
insertion of an IUD left in situ and changing 
needs for contraception or fertility.28 The 
study shows that women can benefit 
significantly from choosing either usual 
medical or LNG-IUS treatment. Just under 
half of women may be expected to retain 
their LNG-IUS at 5 years, while most have 
ceased usual oral treatments by this stage. 
Women able to choose LNG-IUS, if suited to 
their circumstances, may experience less 
discontinuation of treatment, and a better 
effect at 2 years.12 This will not suit all 
women however, as 36% in the current 
trial had had their LNG-IUS removed by 
2 years because of persisting HMB or 
unpredictability of bleeding12 and this is a 
well-recognised problem.29
The low rates of progression to surgical 
intervention observed, 5 years from 
initial presentation with HMB to their GP, 
emphasise the feasibility and importance of 
treating women with HMB in primary care. 
Avoiding referrals to secondary care may 
reduce high operative intervention rates.6,30 
Wider public awareness is needed to 
encourage women to seek help for HMB 
as they are likely to benefit from LNG-
IUS or usual medical treatment in primary 
care. Commensurate availability of expertise 
to offer this range of medical treatments 
should be ensured. While the present data 
suggest that the earlier superiority of LNG-
IUS over the first 2 years was not sustained 
at 5 years, further research to confirm 
this by assessing patient satisfaction with 
and acceptability of treatments would be 
helpful. Longitudinal qualitative research is 
needed to explore and understand women’s 
decisions in choosing treatments for HMB 
and experiences of using them over time. 
The present authors intend to follow-up 
patients to 10 years, when it is expected that 
around half of the cohort will have reached 
the menopause, to assess further patterns 
of treatment use and surgical intervention 
rates.
This pragmatic trial confirms that women 
affected by HMB, with no significant clinical 
risk factors on history or examination, 
can be safely helped by initiating medical 
treatments in primary care, with long-term 
benefit in reducing the effects of HMB on 
their quality of life. 
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